<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"><channel><title><![CDATA[AriBio Co., Ltd. 보도자료 - 뉴스와이어]]></title><link>https://www.newswire.co.kr/?md=A10&amp;act=article&amp;no=39493></link><description><![CDATA[AriBio Co., Ltd. 보도자료 - 뉴스와이어 RSS 서비스]]></description><lastBuildDate>Fri, 01 May 2026 19:21:03 +0900</lastBuildDate><copyright>Copyright (c) 2004~2026 Korea Newswire All rights reserved</copyright><image><url><![CDATA[https://file.newswire.co.kr/data/upfile/company_img/2021/12/12_1026003021_20211221164232_7469052934.gif]]></url></image><language>ko-KR</language><item><title><![CDATA[The Potential of PDE5 Inhibitors, Such as AriBio’s AR1001, the Lead Clinical Candidate for Alzheimer’s Disease, Confirmed in a Recent Independent Study]]></title><link>https://www.newswire.co.kr/newsRead.php?no=936945</link><description><![CDATA[SEONGNAM, South Korea--(Business Wire/Korea Newswire)--A recently published research article in Nature Aging by a Cleveland Clinic Genomic Medicine Institute (GMI) research team, led by Feixiong Cheng, Ph.D., entitled “Endophenotype-based in silico network medicine discovery combined with insurance record data mining identifies sildenafil as a candidate drug for Alzheimer’s disease” showed the poten...]]></description><pubDate>Tue, 21 Dec 2021 17:10:00 +0900</pubDate></item><item><title><![CDATA[아리바이오, 독립 연구 통해 알츠하이머병 치료 주요 후보 물질 AR1001 등 PDE5 억제제 치료 가능성 확인]]></title><link>https://www.newswire.co.kr/newsRead.php?no=936946</link><description><![CDATA[성남, 한국--(Business Wire/뉴스와이어)--페이슝 쳉(Feixiong Cheng) 박사가 이끄는 클리블랜드 클리닉 유전자 의학 연구소(GMI)가 ’네이처 에이징(Nature Aging)’에 ’엔도페노타입 기반 인 실리코 네트워크의 의학적 발견 및 보험 기록 데이터 마이닝을 통한 알츠하이머병 후보 치료제로서의 실데나필 식별(Endophenotype-based in silico network medicine discovery combined with insurance record data mining ...]]></description><pubDate>Tue, 21 Dec 2021 17:10:00 +0900</pubDate></item></channel></rss>